To print this article, all you need is to be registered or login on Mondaq.com.
Bethany Hills, Chair of Mintz Levin's FDA practice explains
why the firm's well-established Health Care, Mergers &
Acquisitions, and Intellectual Property practices, coupled with the
firm's work in the life sciences industry, made Mintz Levin a
great place to establish an FDA Practice.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
The U.S. Department of Justice's (DOJ) April 24, 2024, publication of its final rule on website accessibility for state and local governments under Title II of the Americans...
The purpose of this quarterly tracker is to identify key federal and state health AI policy activity. Below reflects federal legislative and regulatory activity to date related to AI...
Parties involved in or considering health care transactions in California have been focused on navigating the new rules set by California's Office of Health Care Affordability (OHCA)...
Partner Sarah Hogan has contributed to American Health Law Association's second edition of Health Care Contracts: A Clause-by-Clause Guide to Drafting and Negotiation...
According to an April 2024 press release, Alvotech and Teva's Selarsdi™ (ustekinumab-aekn) was approved by the FDA on April 16 as a biosimilar of Janssen / Johnson & Johnson's Stelara® (ustekinumab).
No centralized framework for the regulation of artificial intelligence in the United States currently exists. That said, the flurry of regulatory policymaking and legislation...
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.